|
WO2004007529A2
(en)
|
2002-07-15 |
2004-01-22 |
The Trustees Of Princeton University |
Iap binding compounds
|
|
US7727713B2
(en)
|
2001-06-20 |
2010-06-01 |
Nuevolution A/S |
Templated molecules and methods for using such molecules
|
|
US10731151B2
(en)
|
2002-03-15 |
2020-08-04 |
Nuevolution A/S |
Method for synthesising templated molecules
|
|
AU2003247266A1
(en)
|
2002-08-01 |
2004-02-23 |
Nuevolution A/S |
Multi-step synthesis of templated molecules
|
|
CN102838654B
(zh)
|
2002-10-30 |
2016-05-18 |
纽韦卢森公司 |
合成双功能复合物的方法
|
|
DE60330406D1
(de)
|
2002-12-19 |
2010-01-14 |
Nuevolution As |
Durch quasizufallsstrukturen und funktionen geführte synthesemethode
|
|
US20070026397A1
(en)
|
2003-02-21 |
2007-02-01 |
Nuevolution A/S |
Method for producing second-generation library
|
|
ATE447626T1
(de)
|
2003-09-18 |
2009-11-15 |
Nuevolution As |
Methode zur gewinnung struktureller informationen kodierter moleküle und zur selektion von verbindungen
|
|
US7345081B2
(en)
|
2004-03-23 |
2008-03-18 |
Genentech, Inc. |
Azabicyclo-octane inhibitors of IAP
|
|
PL2253614T3
(pl)
|
2004-04-07 |
2013-03-29 |
Novartis Ag |
Inhibitory IAP
|
|
KR100926203B1
(ko)
|
2004-07-02 |
2009-11-09 |
제넨테크, 인크. |
Iap의 억제제
|
|
JP5230865B2
(ja)
|
2004-07-15 |
2013-07-10 |
テトラロジック ファーマシューティカルズ コーポレーション |
Iap結合性化合物
|
|
MX2007007195A
(es)
|
2004-12-20 |
2007-10-08 |
Genentech Inc |
Inhibidores de pirrolidina de iap.
|
|
EA012810B1
(ru)
|
2005-02-25 |
2009-12-30 |
Тетралоджик Фармасеутикалс |
Димерные ингибиторы ингибиторов белков апоптоза (iap)
|
|
WO2006122408A1
(en)
*
|
2005-05-18 |
2006-11-23 |
Aegera Therapeutics Inc. |
Bir domain binding compounds
|
|
US20080021198A1
(en)
*
|
2005-10-12 |
2008-01-24 |
Yigong Shi |
Modulators of protein phosphatase 2A and PP2A methyl esterase
|
|
AU2006308453B9
(en)
|
2005-10-25 |
2011-12-01 |
Pharmascience Inc. |
IAP BIR domain binding compounds
|
|
LT3018206T
(lt)
|
2005-12-01 |
2021-12-10 |
Nuevolution A/S |
Fermentiniai kodavimo būdai, skirti didelių bibliotekų efektyviai sintezei
|
|
WO2007106192A2
(en)
|
2005-12-19 |
2007-09-20 |
Genentech, Inc. |
Inhibitors of iap
|
|
TWI504597B
(zh)
*
|
2006-03-16 |
2015-10-21 |
Pharmascience Inc |
結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
|
|
BRPI0711591A2
(pt)
|
2006-05-16 |
2011-11-16 |
Aegera Therapeutics, Inc. |
composto de ligação de domìnio bir da iap
|
|
MX2009000824A
(es)
|
2006-07-24 |
2009-02-04 |
Tetralogic Pharmaceuticals Cor |
Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
|
|
JP5452223B2
(ja)
|
2006-07-24 |
2014-03-26 |
テトラロジック ファーマシューティカルズ コーポレーション |
Iap阻害剤
|
|
WO2008014229A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
PE20110217A1
(es)
|
2006-08-02 |
2011-04-01 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
|
US20080153773A1
(en)
*
|
2006-08-08 |
2008-06-26 |
Yigong Shi |
Modulators of phosphotyrosyl phosphatase activator
|
|
AU2007307763A1
(en)
*
|
2006-10-12 |
2008-04-17 |
Novartis Ag |
Pyrrolydine derivatives as IAP inhibitors
|
|
WO2008060791A2
(en)
*
|
2006-10-13 |
2008-05-22 |
The Trustees Of The University Of Princeton |
Modulators of protein phosphatase 2a
|
|
CN101605786A
(zh)
|
2006-12-19 |
2009-12-16 |
健泰科生物技术公司 |
细胞凋亡抑制剂的咪唑并吡啶抑制剂
|
|
NZ598890A
(en)
|
2007-04-30 |
2013-10-25 |
Genentech Inc |
Inhibitors of iap
|
|
JP2010528587A
(ja)
*
|
2007-05-07 |
2010-08-26 |
テトラロジック ファーマシューティカルズ コーポレーション |
アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてTNFα遺伝子の発現を用いる方法
|
|
WO2008144925A1
(en)
*
|
2007-05-30 |
2008-12-04 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
|
US20090274682A1
(en)
*
|
2008-02-05 |
2009-11-05 |
The Trustees Of Princeton University |
Demethylation and inactivation of protein phosphatase 2a
|
|
US20090233858A1
(en)
*
|
2008-02-26 |
2009-09-17 |
The Trustees Of Princeton University |
Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
|
|
US20110117081A1
(en)
*
|
2008-05-05 |
2011-05-19 |
Aegera Therapeutics, Inc. |
Functionalized pyrrolidines and use thereof as iap inhibitors
|
|
TW201011006A
(en)
*
|
2008-06-16 |
2010-03-16 |
Nuevolution As |
IAP binding compounds
|
|
US20110171171A1
(en)
*
|
2008-06-27 |
2011-07-14 |
Aegera Therapeutics, Inc. |
Bridged secondary amines and use thereof as iap bir domain binding compounds
|
|
US8835393B2
(en)
|
2008-08-02 |
2014-09-16 |
Genentech, Inc. |
Inhibitors of IAP
|
|
JP2012500272A
(ja)
*
|
2008-08-16 |
2012-01-05 |
ジェネンテック, インコーポレイテッド |
Iapのアザインドールインヒビター
|
|
US8283372B2
(en)
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
|
JP2013505446A
(ja)
|
2009-09-18 |
2013-02-14 |
ノバルティス アーゲー |
Iap阻害剤化合物のためのバイオマーカー
|
|
NZ602368A
(en)
|
2010-02-12 |
2014-10-31 |
Pharmascience Inc |
Iap bir domain binding compounds
|
|
SI2558577T1
(sl)
|
2010-04-16 |
2019-05-31 |
Nuevolution A/S |
Bifunkcionalni kompleksi in metode za pripravo in uporabo takšnih kompleksov
|
|
UY33794A
(es)
|
2010-12-13 |
2012-07-31 |
Novartis Ag |
Inhibidores diméricos de las iap
|
|
KR20150011822A
(ko)
|
2012-05-04 |
2015-02-02 |
노파르티스 아게 |
Iap 억제제 요법을 위한 바이오마커
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
MX366978B
(es)
|
2013-03-15 |
2019-08-01 |
Novartis Ag |
Conjugados de anticuerpo - farmaco.
|
|
JP6768522B2
(ja)
|
2014-06-04 |
2020-10-14 |
サンフォード−バーンハム メディカル リサーチ インスティテュート |
Hiv治療におけるアポトーシスタンパク質阻害剤(iap)のアンタゴニストの使用
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
MX2017001946A
(es)
|
2014-08-12 |
2017-06-19 |
Novartis Ag |
Conjugados de farmacos con anticuerpos anti-cdh6.
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
WO2017044592A1
(en)
*
|
2015-09-08 |
2017-03-16 |
The Regents Of The University Of California |
Conjugated anticancer smac analogs
|
|
CR20180229A
(es)
|
2015-10-29 |
2018-08-24 |
Novartis Ag |
Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
WO2018163051A1
(en)
|
2017-03-06 |
2018-09-13 |
Novartis Ag |
Methods of treatment of cancer with reduced ubb expression
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
US20200362058A1
(en)
|
2017-05-24 |
2020-11-19 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
KR102920712B1
(ko)
|
2017-05-24 |
2026-01-30 |
노파르티스 아게 |
항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
EP3873532A1
(de)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign-antikörper-arzneimittelkonjugate
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
AU2019409132B2
(en)
|
2018-12-21 |
2026-08-06 |
Novartis Ag |
Antibodies to PMEL17 and conjugates thereof
|
|
EP3924054B1
(de)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5- (piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dionderivate und ihre verwendungen
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
JP2022542437A
(ja)
|
2019-08-02 |
2022-10-03 |
ランティオペプ ベスローテン ヴェンノーツハップ |
癌の処置に用いるアンジオテンシン2型(at2)受容体アゴニスト
|
|
US12678509B2
(en)
|
2019-11-08 |
2026-07-14 |
Sanford Burnham Prebys Medical Discovery Institute |
Inhibitor of apoptosis (IAP) protein antagonists
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
US20230056604A1
(en)
|
2020-01-20 |
2023-02-23 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
US20230332104A1
(en)
|
2020-06-11 |
2023-10-19 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
EP4168007A1
(de)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosierschema mit 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivaten
|
|
EP4188549A1
(de)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroarylsubstituierte 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dionderivate und verwendungen davon
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
AU2022258829A1
(en)
|
2021-04-16 |
2023-10-26 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
JP2025524064A
(ja)
|
2022-07-26 |
2025-07-25 |
ノバルティス アーゲー |
Akr1c3依存性kars阻害剤の結晶形態
|